Evidence map›Paper›PMID 36224327›Full record

ArticleScientific reports2022

In vitro inhibition of SARS-CoV-2 Infection by dry algae powders.

Daniel Garcia-Ruiz, Erendira Villalobos-Sánchez, David Alam-Escamilla, Darwin Elizondo-Quiroga

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 16 citations in OpenAlex.

  1. International journal of molecular sciences · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Daniel Garcia-Ruiz *Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco (CIATEJ), Av. Normalistas 800, Colinas de la Normal, 44270, Guadalajara, Jalisco, Mexico.
Erendira Villalobos-Sánchez *Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco (CIATEJ), Av. Normalistas 800, Colinas de la Normal, 44270, Guadalajara, Jalisco, Mexico.
David Alam-EscamillaCREAMOS MAS S.A. DE C.V, Calle Monte Albán No. 965. Colonia. Independencia Oriente, C.P. 44340, Guadalajara, Jalisco, Mexico.
Darwin Elizondo-QuirogaMedical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco (CIATEJ), Av. Normalistas 800, Colinas de la Normal, 44270, Guadalajara, Jalisco, Mexico. delizondo@ciatej.mx.
Secretaría de Salud de Jalisco · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chlorella spp., Spirulina spp., and fucoidan dry powders, are commercialized as food supplements and are considered safe for human consumption. Their broad-spectrum antiviral properties have been studied, however, their effect against SARS-CoV-2 remains unknown. We investigated the potential antiviral activity of three algae powders: Chlorella vulgaris, Arthrospira maxima (Spirulina) and fucoidan purified from marine brown algae Sargassum spp. against SARS-CoV-2 infection in vitro. Vero cells were incubated with 70 μg/ml of each algae powder and either 50 or 100 TCID

Indexed as

Chlorella vulgarisCOVID-19 Drug TreatmentAnimalsAntiviral AgentsChlorocebus aethiopsDimethyl SulfoxideHumansPowdersRNA, ViralSARS-CoV-2SolventsVero CellsAntiviral AgentsDimethyl SulfoxidePowdersRNA, ViralSolvents

Identifiers

PMID36224327
PMCPMC9555251
OpenAlexW4304694268

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.